Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017

Introducción: Para el 2030 se estima una población diabética de 33 millones de personas en Latinoamérica. La prevalencia global es del 25,2%, en hispanos varía del 30 al 50% con unos costos por complicaciones alrededor de 493 millones de dólares. La prevención está asociada a la efectividad de los p...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:: 2018

Institución:: Universidad del Rosario

Repositorio:: Repositorio EdocUR - U. Rosario

Idioma:: spa

id	EDOCUR2_3b4182ddfcfa0a6868c04c71ec1095a6
oai_identifier_str	oai:repository.urosario.edu.co:10336/18648
network_acronym_str	EDOCUR2
network_name_str	Repositorio EdocUR - U. Rosario
repository_id_str
dc.title.spa.fl_str_mv	Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017
dc.title.alternative.spa.fl_str_mv	Retinopatía diabética : prevalencia en diabéticos tipo 2 en un hospital de referencia de Bogotá entre 2012 – 2017
title	Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017
spellingShingle	Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017 Edema macular Prevalencia Retinopatía diabética Ceguera Diabetes mellitus Enfermedades retinal hemorrhages diabetes complications diabetic retinopathy macular edema blindness Diabetes Enfermedades de la retina Enfermedades de los ojos
title_short	Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017
title_full	Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017
title_fullStr	Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017
title_full_unstemmed	Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017
title_sort	Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017
dc.contributor.advisor.none.fl_str_mv	Navarro Naranjo, Pedro Iván
dc.subject.spa.fl_str_mv	Edema macular Prevalencia Retinopatía diabética Ceguera Diabetes mellitus
topic	Edema macular Prevalencia Retinopatía diabética Ceguera Diabetes mellitus Enfermedades retinal hemorrhages diabetes complications diabetic retinopathy macular edema blindness Diabetes Enfermedades de la retina Enfermedades de los ojos
dc.subject.ddc.spa.fl_str_mv	Enfermedades
dc.subject.keyword.spa.fl_str_mv	retinal hemorrhages diabetes complications diabetic retinopathy macular edema blindness
dc.subject.lemb.spa.fl_str_mv	Diabetes Enfermedades de la retina Enfermedades de los ojos
description	Introducción: Para el 2030 se estima una población diabética de 33 millones de personas en Latinoamérica. La prevalencia global es del 25,2%, en hispanos varía del 30 al 50% con unos costos por complicaciones alrededor de 493 millones de dólares. La prevención está asociada a la efectividad de los programas de detección de la retinopatía diabética (RD). Objetivo: Estimar la prevalencia de RD en DM tipo 2 en una entidad hospitalaria de la ciudad de Bogotá entre los años 2012 - 2017. Diseño: Estudio observacional descriptivo, de corte transversal y de prevalencia. Metodología: La prevalencia de la RD se calculó estimando la proporción de diabéticos tipo 2 con RD sobre el total de diabéticos tipo 2 de una entidad hospitalaria de la ciudad de Bogotá durante el periodo 2012-2017. Se recolectaron variables sociodemográficas, tiempo de evolución de la enfermedad, hipertensión arterial, tipo de tratamiento y complicaciones por RD. Se validó la base de datos estimando el grado de concordancia (kappa) entre el sistema electrónico de diagnóstico (H360) y el diagnóstico clínico dado por el examen oftalmológico. Se utilizó pruebas de correlación (Spearman), análisis de variables con test de Mann-Whitnney, Chi cuadrado y test de concordancia. Resultados: La prevalencia de RD en DM tipo 2 atendidos en la entidad hospitalaria de la ciudad de Bogotá fue de 7,3% para la muestra seleccionada. El 62% fueron hombres con una edad mediana de 71 años (RIC=15) y una mediana de tiempo de evolución de la enfermedad de 17 años (RIC=12). El 93,8 % eran hipertensos y el 42,1 % en tratamiento con insulina. La complicación más frecuente por RD fue la hemorragia vítrea (11,2%), glaucoma neovascular (5%), oclusiones vasculares (4,2%) y desprendimiento de retina traccional (4,2%). La concordancia observada fue del 94% (IC 95% -0,16 -0,62 z=2,646 p=0,008). Conclusión: La prevalencia de RD en la entidad hospitalaria durante el quinquenio 2012-2017 fue del 7,3%. La DM2 con RD fue más prevalente en hombres con hipertensión arterial, con largo tiempo de evolución de la enfermedad y quienes estaban bajo tratamiento con insulina. Se sugiere la implementación de programas de prevención para reducir las complicaciones visuales por RD.
publishDate	2018
dc.date.accessioned.none.fl_str_mv	2018-10-24T13:16:02Z
dc.date.available.none.fl_str_mv	2018-10-24T13:16:02Z
dc.date.created.none.fl_str_mv	2018-08-24
dc.date.issued.none.fl_str_mv	2018
dc.type.eng.fl_str_mv	bachelorThesis
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.spa.spa.fl_str_mv	Trabajo de grado
dc.identifier.doi.none.fl_str_mv	https://doi.org/10.48713/10336_18648
dc.identifier.uri.none.fl_str_mv	http://repository.urosario.edu.co/handle/10336/18648
url	https://doi.org/10.48713/10336_18648 http://repository.urosario.edu.co/handle/10336/18648
dc.language.iso.none.fl_str_mv	spa
language	spa
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv	Abierto (Texto Completo)
rights_invalid_str_mv	Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad del Rosario
dc.publisher.department.spa.fl_str_mv	Facultad de medicina
institution	Universidad del Rosario
dc.source.bibliographicCitation.spa.fl_str_mv	Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844-51. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice. 2017;128:40-50. Artículos selectos - Observatorio Diabetes Colombia - ODC. 2017. Guia clinica Retinopatia Diabetica paao ico 16 may 2016. 2017. Suarez Flórez LE, Chavarriaga Ríos MC. Prevalencia de diabetes mellitus autoreportada y factores asociados en los adultos de 60-64 años de Medellín y área metropolitana, participantes en la encuesta nacional de demografía y salud y la encuesta de situación de salud. Revista CES Salud Pública. 2014;5(1):21-37. Rodriguez FJ, Brieke AC, Guerrero J, Porras A, Zaraband MP. Prevalencia de retinopatía diabética en pacientes diabéticos en consulta privada en Bogotá, Colombia desde el 2000 hasta el 2007. Revista Sociedad Colombiana de Oftalmología. 2009;42(2):197-204. Alad. Guías ALAD sobre diagnóstico, control y tratamiento de la diabetes mellitus tipo 2 con medicina basada en evidencia. 2013. Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. San Luis Valley Diabetes Study. Diabetes. 1989;38(10):1231-7. Varma R, Ying-Lai M, Klein R, Azen SP. Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(6):1132-40. Schellini SA, Carvalho GM, Rendeiro FS, Padovani CR, Hirai FE. Prevalence of diabetes and diabetic retinopathy in a Brazilian population. Ophthalmic Epidemiol. 2014;21(1):33-8. Villena JE, Yoshiyama CA, Sanchez JE, Hilario NL, Merin LM. Prevalence of diabetic retinopathy in Peruvian patients with type 2 diabetes: results of a hospital-based retinal telescreening program. Rev Panam Salud Publica. 2011;30(5):408-14. Prado-Serrano A. Prevalencia e retinopatía diabética en l población Mexicana. Revista Mexica Oftalmología. 2009;83(5):261-66. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of Diabetic Retinopathy in Various Ethnic Groups: A Worldwide Perspective. Survey of Ophthalmology. 2012;57(4):347-70. Federation ID. Diabetic Retinopathy Barometer 2017 [Available from: https://www.idf.org/e-library/epidemiology-research/other-resources.html. Sanchez Rivero G, Academia de la historia de la Medicina C. HISTORIA DE LA DIABETES. Gac Med Bol. 2007;30(2):74-8. PÉRez B F. Epidemiología y fisiopatología de la diabetes mellitus tipo 2. Revista Médica Clínica Las Condes. 2009;20(5):565-71. Poitout, V., & Robertson, R. P. (2008). Glucolipotoxicity: Fuel Excess and β-Cell Dysfunction. Endocrine Reviews, 29(3), 351–366. 2007-0023. Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clinical & Experimental Ophthalmology. 2016;44(4):260-77. Ada. Standards of Medical Care in Diabetes - 2017. Diabetes Care. 2017;40(Supplement 1). Bennett WL, Odelola OA, Wilson LM, Bolen S, Selvaraj S, Robinson KA, et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med. 2012;156(1 Pt 1):27-36. Federation ID. IDF Diabetes Atlas 7th edition 2017 [Available from: https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/13:diabetes-atlas-seventh-edition.html. Aschner P. Epidemiología de la diabetes en Colombia. Avances en Diabetología. 2010;26(2):95-100. Prevalencia de la diabetes mellitus en Colombia - Observatorio Diabetes Colombia - ODC. 2017. MinSalud. Guía de práctica clínica (GPC) para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Bogotá, Colombia: Colciencias; 2015. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994;37(3):278-85. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497-503. Ramachandran A, Snehalatha C, Sasikala R, Satyavani K, Vijay V. Vascular complications in young Asian Indian patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2000;48(1):51-6. Bonney M, Hing SJ, Fung AT, Stephens MM, Fairchild JM, Donaghue KC, et al. Development and progression of diabetic retinopathy: adolescents at risk. Diabet Med. 1995;12(11):967-73. Broadbent DM, Scott JA, Vora JP, Harding SP. Prevalence of diabetic eye disease in an inner city population: the Liverpool Diabetic Eye Study. Eye (Lond). 1999;13 ( Pt 2):160-5. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156-63. Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care. 2005;28(8):1954-8. Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26(6):1731-7. Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology. 1998;105(3):406-11. Mitchell P, Moffitt PS, Beaumont P. Prevalence of vision-threatening diabetic retinopathy in Newcastle, Australia. Tohoku J Exp Med. 1983;141 Suppl:379-83. He S, Guo Y, Li Z. [Epidemiologic study of diabetic retinopathy in Capital Steel Company]. Zhonghua Yan Ke Za Zhi. 1997;33(5):381-3. Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116(3):461-7. Chiang PP, Lamoureux EL, Cheung CY, Sabanayagam C, Wong W, Tai ES, et al. Racial differences in the prevalence of diabetes but not diabetic retinopathy in a multi-ethnic Asian population. Invest Ophthalmol Vis Sci. 2011;52(10):7586-92. Burger W, Hovener G, Dusterhus R, Hartmann R, Weber B. Prevalence and development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. A longitudinal study. Diabetologia. 1986;29(1):17-22. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-806. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35(3):592-6. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859-68. Leske MC, Wu SY, Hennis A, Nemesure B, Hyman L, Schachat A. Incidence of diabetic retinopathy in the Barbados Eye Studies. Ophthalmology. 2003;110(5):941-7. Song H, Liu L, Sum R, Fung M, Yap MK. Incidence of diabetic retinopathy in a Hong Kong Chinese population. Clin Exp Optom. 2011;94(6):563-7. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care. 2009;32(12):2307-13. Villegas Perrasse A, Universidad de Antioquia A, Colombia, Abad SB, Empresa Promotora de Salud Punto Salud Susalud M, Colombia, Faciolince S, Institución Prestadora de Salud Comfama M, Colombia, et al. Controlling diabetes mellitus and its complications in Medellín, Colombia, 2001-2003. Rev Panam Salud Publica. 2006;20(6):393-402. Pena F. Prevalencia de ceguera en Colombia. Estudio poblacional en una comunidad urbana.- 26/2/04. Revista Franja Ocular. 2001;2(13):3-6. Galvis V. Prevalencia de ceguera en el Departamento de Santander - Colombia. 12. 2010. Colombia MdSPSd. Asis-salud-visual-colombia-2016. 2017. Joslin EP, Kahn CR. Joslin's Diabetes Mellitus: Edited by C. Ronald Kahn ... [et Al.]: Lippincott Williams & Willkins; 2005. G V. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. 2018. International Council of Ophthalmology : Enhancing Eye Care : Diabetic Eye Care 2018 [Available from: http://www.icoph.org/enhancing_eyecare/diabetic_eyecare.html. Harding S, Greenwood R, Aldington S, Gibson J, Owens D, Taylor R, et al. Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet Med. 2003;20(12):965-71. Ophthalmology AAo. International Clinical Classification System for Diabetic Retinopathy and Diabetic Macular Edema - 2012. 5/16. Organization CfIOoMSicwtWH. International Ethical Guidelines for Health-related Research Involving Humans. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS); 2016. p. 1 - 122. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000;23(8):1084-91. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 2008;359(15):1577-89. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341(8856):1306-9. Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014;121(12):2443-51. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72. Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. Lancet. 2008;372(9647):1361-3. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40-51. Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:Cd006127. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med. 1994;154(19):2169-78. Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446-55. Rema M, Srivastava BK, Anitha B, Deepa R, Mohan V. Association of serum lipids with diabetic retinopathy in urban South Indians--the Chennai Urban Rural Epidemiology Study (CURES) Eye Study--2. Diabet Med. 2006;23(9):1029-36. Rooney D, Lye WK, Tan G, Lamoureux EL, Ikram MK, Cheng CY, et al. Body mass index and retinopathy in Asian populations with diabetes mellitus. Acta Diabetol. 2015;52(1):73-80. Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol. 2007;52(2):180-95. Lu J, Hou X, Zhang L, Jiang F, Hu C, Bao Y, et al. Association between body mass index and diabetic retinopathy in Chinese patients with type 2 diabetes. Acta Diabetol. 2015;52(4):701-8. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006;12 Suppl 1:34-41. Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 2016;17(9). Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M. Up-regulation of vascular endothelial growth factor and down-regulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes. Int J Tissue React. 2002;24(4):137-42. Srinivasan V, Sulochana KN. Effect of adiponectin on expression of vascular endothelial growth factor and pigment epithelium-derived factor: An in vitro study. Indian Journal of Pharmacology. 2015;47(1):117-20. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol. 2008;92(4):548-51. He R, Shen J, Liu F, Zeng H, Li L, Yu H, et al. Vitamin D deficiency increases the risk of retinopathy in Chinese patients with type 2 diabetes. Diabet Med. 2014;31(12):1657-64. Huang YC, Lin JM, Lin HJ, Chen CC, Chen SY, Tsai CH, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011;118(4):642-8. Fu YP, Hallman DM, Gonzalez VH, Klein BE, Klein R, Hayes MG, et al. Identification of Diabetic Retinopathy Genes through a Genome-Wide Association Study among Mexican-Americans from Starr County, Texas. J Ophthalmol. 2010;2010. Symposium on the Treatment of Diabetic R, Goldberg MF, Fine SL, Symposium on the Treatm EDR, editors. Symposium on the Treatment of Diabetic Retinopathy Airlie House, Warrenton, Virginia, September 29 to October 1, 19681969; Arlington, Va: U.S. Dep. of Health, Education, and Welfare, Public Health Service, Neurological and Sensory Disease Control Program, Diabetes and Arthritis Control Program. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978;85(1):82-106. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):823-33. Zhang X, Saaddine JB, Chou C-F, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of Diabetic Retinopathy in the United States, 2005–2008. JAMA : the journal of the American Medical Association. 2010;304(6):649-56. Fong DS, Ferris FL, 3rd, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127(2):137-41. Estacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis. 1998;31(6):947-53. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-44. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127(3):245-51. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128(3):289-96. Stefanini FR, Badaro E, Falabella P, Koss M, Farah ME, Maia M. Anti-VEGF for the management of diabetic macular edema. J Immunol Res. 2014;2014:632307. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, et al. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135(6):558-68. Shah AR, Gardner TW. Diabetic retinopathy: research to clinical practice. Clin Diabetes Endocrinol. 2017;3:9. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2010;117(6):1064-77.e35. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014(11):Cd011234. Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. Jama. 2015;314(20):2137-46. Kim JH, Kwon HS, Park YM, Lee JH, Kim MS, Yoon KH, et al. Prevalence and associated factors of diabetic retinopathy in rural Korea: the Chungju metabolic disease cohort study. J Korean Med Sci. 2011;26(8):1068-73. Rodriguez-Poncelas A, Miravet-Jimenez S, Casellas A, Barrot-De La Puente JF, Franch-Nadal J, Lopez-Simarro F, et al. Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). Br J Ophthalmol. 2015;99(12):1628-33. Alonso-Moran E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Marques Gonzalez ML, Toro Polanco N, et al. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. BMC Public Health. 2014;14:1059. Covarrubias T, Delgado I, Rojas D, Coria M. [Coverage of a screening program and prevalence of diabetic retinopathy in primary carec]. Rev Med Chil. 2017;145(5):564-71. Ruta LM, Magliano DJ, Lemesurier R, Taylor HR, Zimmet PZ, Shaw JE. Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. Diabet Med. 2013;30(4):387-98. Polack S, Yorston D, Lopez-Ramos A, Lepe-Orta S, Baia RM, Alves L, et al. Rapid assessment of avoidable blindness and diabetic retinopathy in Chiapas, Mexico. Ophthalmology. 2012;119(5):1033-40. Herman WH, Aubert RE, Engelgau MM, Thompson TJ, Ali MA, Sous ES, et al. Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet Med. 1998;15(12):1045-51. Kadiki OA, Roaed RB. Epidemiological and clinical patterns of diabetes mellitus in Benghazi, Libyan Arab Jamahiriya. East Mediterr Health J. 1999;5(1):6-13. Farnkvist LM, Lundman BM. Outcomes of diabetes care: a population-based study. Int J Qual Health Care. 2003;15(4):301-7. Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia. 2010;53(10):2147-54. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. Prevalence and Risk Factors for Diabetic Retinopathy: The Singapore Malay Eye Study. Ophthalmology. 2008;115(11):1869-75. Thomas RL, Dunstan F, Luzio SD, Roy Chowdury S, Hale SL, North RV, et al. Furtado JM, Lansingh VC, Carter MJ, Milanese MF, Peña BN, Ghersi HA, et al. Causes of Blindness and Visual Impairment in Latin America. Survey of Ophthalmology. 2012;57(2):149-77. Cass H, Landers J, Benitez P. Causes of blindness among hospital outpatients in Ecuador. Clin Exp Ophthalmol. 2006;34(2):146-51. Cano MR. Prevalence of diabetic retinopathy and barriers to uptake of eye care services by diabetic patients at the Social Security Institute Central Hospital in Asunción, Paraguay. Community Eye Health. 2007;20(61):10-1. Alonso Porcel C, Martinez Iban M, Arboleya Alvarez L, Suarez Gil P, Sanchez Rodriguez LM. [Diabetic retinopathy screening programme in primary health care. Diagnostic concordance between family and eye care practitioners]. Semergen. 2016;42(6):357-62.
dc.source.instname.spa.fl_str_mv	instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv	reponame:Repositorio Institucional EdocUR
bitstream.url.fl_str_mv	https://repository.urosario.edu.co/bitstreams/d322cbbc-0c8f-40ee-a7a4-624a839dc83e/download https://repository.urosario.edu.co/bitstreams/999e97ea-21be-47c0-a22b-f40234c9b138/download https://repository.urosario.edu.co/bitstreams/95079407-60ea-4137-b972-4787b9a5f96a/download https://repository.urosario.edu.co/bitstreams/1f39aa37-c7b9-46ae-9039-7e438f9d6870/download
bitstream.checksum.fl_str_mv	fab9d9ed61d64f6ac005dee3306ae77e 7afffe0583fe869433be57a2109c5798 606904216f1051bf3b6a9c923c6ac4e1 1a47518809b81157395cb6c0617af19a
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio institucional EdocUR
repository.mail.fl_str_mv	edocur@urosario.edu.co
_version_	1814167563407458304
spelling	Navarro Naranjo, Pedro Ivándb15a411-0000-4253-8346-15530bf90fd2600Prada Ramirez, Lilian JeannetteEspecialista en Epidemiología (en Convenio con el CES)Part timea7fac4c4-b8d6-407a-b17f-2eada3f4e7ec6002018-10-24T13:16:02Z2018-10-24T13:16:02Z2018-08-242018Introducción: Para el 2030 se estima una población diabética de 33 millones de personas en Latinoamérica. La prevalencia global es del 25,2%, en hispanos varía del 30 al 50% con unos costos por complicaciones alrededor de 493 millones de dólares. La prevención está asociada a la efectividad de los programas de detección de la retinopatía diabética (RD). Objetivo: Estimar la prevalencia de RD en DM tipo 2 en una entidad hospitalaria de la ciudad de Bogotá entre los años 2012 - 2017. Diseño: Estudio observacional descriptivo, de corte transversal y de prevalencia. Metodología: La prevalencia de la RD se calculó estimando la proporción de diabéticos tipo 2 con RD sobre el total de diabéticos tipo 2 de una entidad hospitalaria de la ciudad de Bogotá durante el periodo 2012-2017. Se recolectaron variables sociodemográficas, tiempo de evolución de la enfermedad, hipertensión arterial, tipo de tratamiento y complicaciones por RD. Se validó la base de datos estimando el grado de concordancia (kappa) entre el sistema electrónico de diagnóstico (H360) y el diagnóstico clínico dado por el examen oftalmológico. Se utilizó pruebas de correlación (Spearman), análisis de variables con test de Mann-Whitnney, Chi cuadrado y test de concordancia. Resultados: La prevalencia de RD en DM tipo 2 atendidos en la entidad hospitalaria de la ciudad de Bogotá fue de 7,3% para la muestra seleccionada. El 62% fueron hombres con una edad mediana de 71 años (RIC=15) y una mediana de tiempo de evolución de la enfermedad de 17 años (RIC=12). El 93,8 % eran hipertensos y el 42,1 % en tratamiento con insulina. La complicación más frecuente por RD fue la hemorragia vítrea (11,2%), glaucoma neovascular (5%), oclusiones vasculares (4,2%) y desprendimiento de retina traccional (4,2%). La concordancia observada fue del 94% (IC 95% -0,16 -0,62 z=2,646 p=0,008). Conclusión: La prevalencia de RD en la entidad hospitalaria durante el quinquenio 2012-2017 fue del 7,3%. La DM2 con RD fue más prevalente en hombres con hipertensión arterial, con largo tiempo de evolución de la enfermedad y quienes estaban bajo tratamiento con insulina. Se sugiere la implementación de programas de prevención para reducir las complicaciones visuales por RD.Introduction: By 2030 a diabetic population of 33 million people in Latin America is estimated. The overall prevalence is 25.2%, in Hispanics it varies from 30 to 50% with complications costs around 493 million dollars. Prevention is associated with the effectiveness of diabetic retinopathy (DR) detection programs. Objective: To estimate the prevalence of RD in type 2 DM in a hostipal between the years 2012 - 2017. Design: Observational, descriptive, cross-sectional and prevalence study. Methodology: The prevalence of DR was calculated by estimating the proportion of type 2 diabetics with DR over the total of type 2 diabetics of a hospital in Bogotá during the period 2012-2017. Sociodemographic variables, time of evolution of the disease, arterial hypertension, type of treatment and complications due to DR were collected. The database was validated estimating the degree of agreement (kappa) between the electronic diagnostic system (H360) and the clinical diagnosis given by the ophthalmological examination. Correlation tests (Spearman), analysis of variables with Mann-Whitney test, Chi square and concordance test were used. Results: The prevalence of DR in Diabetes type 2 treated in the Hospital was 7.3% for the selected sample. 62% were men with a median age of 71 years (IQR = 15) and a median time of evolution of the disease of 17 years (IQR = 12). 93.8% were hypertensive and 42.1% were treated with insulin. The most frequent complication due to RD was vitreous hemorrhage (11.2%), neovascular glaucoma (5%), vascular occlusions (4.2%) and tractional retinal detachment (4.2%). The observed concordance was 94% (95% CI -0.16 -0.62 z = 2.666 p = 0.008). Conclusion: The prevalence of DR in the Hospital during the five-year period 2012-2017 was 7.3%. Type 2 Diabetes with DR was more prevalent in men with hypertension, with a long time of evolution of the disease and those who were under treatment with insulin. It is suggested the implementation of prevention programs to reduce visual complications by DR.2020-11-01 01:01:01: Script de automatizacion de embargos. info:eu-repo/date/embargoEnd/2020-10-31application/pdfhttps://doi.org/10.48713/10336_18648 http://repository.urosario.edu.co/handle/10336/18648spaUniversidad del RosarioFacultad de medicinaAbierto (Texto Completo)EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.http://purl.org/coar/access_right/c_abf2Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844-51.Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64.Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice. 2017;128:40-50.Artículos selectos - Observatorio Diabetes Colombia - ODC. 2017.Guia clinica Retinopatia Diabetica paao ico 16 may 2016. 2017.Suarez Flórez LE, Chavarriaga Ríos MC. Prevalencia de diabetes mellitus autoreportada y factores asociados en los adultos de 60-64 años de Medellín y área metropolitana, participantes en la encuesta nacional de demografía y salud y la encuesta de situación de salud. Revista CES Salud Pública. 2014;5(1):21-37.Rodriguez FJ, Brieke AC, Guerrero J, Porras A, Zaraband MP. Prevalencia de retinopatía diabética en pacientes diabéticos en consulta privada en Bogotá, Colombia desde el 2000 hasta el 2007. Revista Sociedad Colombiana de Oftalmología. 2009;42(2):197-204.Alad. Guías ALAD sobre diagnóstico, control y tratamiento de la diabetes mellitus tipo 2 con medicina basada en evidencia. 2013.Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. San Luis Valley Diabetes Study. Diabetes. 1989;38(10):1231-7.Varma R, Ying-Lai M, Klein R, Azen SP. Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(6):1132-40.Schellini SA, Carvalho GM, Rendeiro FS, Padovani CR, Hirai FE. Prevalence of diabetes and diabetic retinopathy in a Brazilian population. Ophthalmic Epidemiol. 2014;21(1):33-8.Villena JE, Yoshiyama CA, Sanchez JE, Hilario NL, Merin LM. Prevalence of diabetic retinopathy in Peruvian patients with type 2 diabetes: results of a hospital-based retinal telescreening program. Rev Panam Salud Publica. 2011;30(5):408-14.Prado-Serrano A. Prevalencia e retinopatía diabética en l población Mexicana. Revista Mexica Oftalmología. 2009;83(5):261-66.Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of Diabetic Retinopathy in Various Ethnic Groups: A Worldwide Perspective. Survey of Ophthalmology. 2012;57(4):347-70.Federation ID. Diabetic Retinopathy Barometer 2017 [Available from: https://www.idf.org/e-library/epidemiology-research/other-resources.html.Sanchez Rivero G, Academia de la historia de la Medicina C. HISTORIA DE LA DIABETES. Gac Med Bol. 2007;30(2):74-8.PÉRez B F. Epidemiología y fisiopatología de la diabetes mellitus tipo 2. Revista Médica Clínica Las Condes. 2009;20(5):565-71.Poitout, V., & Robertson, R. P. (2008). Glucolipotoxicity: Fuel Excess and β-Cell Dysfunction. Endocrine Reviews, 29(3), 351–366. 2007-0023.Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clinical & Experimental Ophthalmology. 2016;44(4):260-77.Ada. Standards of Medical Care in Diabetes - 2017. Diabetes Care. 2017;40(Supplement 1).Bennett WL, Odelola OA, Wilson LM, Bolen S, Selvaraj S, Robinson KA, et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med. 2012;156(1 Pt 1):27-36.Federation ID. IDF Diabetes Atlas 7th edition 2017 [Available from: https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/13:diabetes-atlas-seventh-edition.html.Aschner P. Epidemiología de la diabetes en Colombia. Avances en Diabetología. 2010;26(2):95-100.Prevalencia de la diabetes mellitus en Colombia - Observatorio Diabetes Colombia - ODC. 2017.MinSalud. Guía de práctica clínica (GPC) para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Bogotá, Colombia: Colciencias; 2015.Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994;37(3):278-85.Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497-503.Ramachandran A, Snehalatha C, Sasikala R, Satyavani K, Vijay V. Vascular complications in young Asian Indian patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2000;48(1):51-6.Bonney M, Hing SJ, Fung AT, Stephens MM, Fairchild JM, Donaghue KC, et al. Development and progression of diabetic retinopathy: adolescents at risk. Diabet Med. 1995;12(11):967-73.Broadbent DM, Scott JA, Vora JP, Harding SP. Prevalence of diabetic eye disease in an inner city population: the Liverpool Diabetic Eye Study. Eye (Lond). 1999;13 ( Pt 2):160-5.Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156-63.Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care. 2005;28(8):1954-8.Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26(6):1731-7.Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology. 1998;105(3):406-11.Mitchell P, Moffitt PS, Beaumont P. Prevalence of vision-threatening diabetic retinopathy in Newcastle, Australia. Tohoku J Exp Med. 1983;141 Suppl:379-83.He S, Guo Y, Li Z. [Epidemiologic study of diabetic retinopathy in Capital Steel Company]. Zhonghua Yan Ke Za Zhi. 1997;33(5):381-3.Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116(3):461-7.Chiang PP, Lamoureux EL, Cheung CY, Sabanayagam C, Wong W, Tai ES, et al. Racial differences in the prevalence of diabetes but not diabetic retinopathy in a multi-ethnic Asian population. Invest Ophthalmol Vis Sci. 2011;52(10):7586-92.Burger W, Hovener G, Dusterhus R, Hartmann R, Weber B. Prevalence and development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. A longitudinal study. Diabetologia. 1986;29(1):17-22.Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-806.Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35(3):592-6.Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859-68.Leske MC, Wu SY, Hennis A, Nemesure B, Hyman L, Schachat A. Incidence of diabetic retinopathy in the Barbados Eye Studies. Ophthalmology. 2003;110(5):941-7.Song H, Liu L, Sum R, Fung M, Yap MK. Incidence of diabetic retinopathy in a Hong Kong Chinese population. Clin Exp Optom. 2011;94(6):563-7.Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care. 2009;32(12):2307-13.Villegas Perrasse A, Universidad de Antioquia A, Colombia, Abad SB, Empresa Promotora de Salud Punto Salud Susalud M, Colombia, Faciolince S, Institución Prestadora de Salud Comfama M, Colombia, et al. Controlling diabetes mellitus and its complications in Medellín, Colombia, 2001-2003. Rev Panam Salud Publica. 2006;20(6):393-402.Pena F. Prevalencia de ceguera en Colombia. Estudio poblacional en una comunidad urbana.- 26/2/04. Revista Franja Ocular. 2001;2(13):3-6.Galvis V. Prevalencia de ceguera en el Departamento de Santander - Colombia. 12. 2010.Colombia MdSPSd. Asis-salud-visual-colombia-2016. 2017.Joslin EP, Kahn CR. Joslin's Diabetes Mellitus: Edited by C. Ronald Kahn ... [et Al.]: Lippincott Williams & Willkins; 2005.G V. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. 2018.International Council of Ophthalmology : Enhancing Eye Care : Diabetic Eye Care 2018 [Available from: http://www.icoph.org/enhancing_eyecare/diabetic_eyecare.html.Harding S, Greenwood R, Aldington S, Gibson J, Owens D, Taylor R, et al. Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet Med. 2003;20(12):965-71.Ophthalmology AAo. International Clinical Classification System for Diabetic Retinopathy and Diabetic Macular Edema - 2012. 5/16.Organization CfIOoMSicwtWH. International Ethical Guidelines for Health-related Research Involving Humans. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS); 2016. p. 1 - 122.Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000;23(8):1084-91.Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 2008;359(15):1577-89.Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341(8856):1306-9.Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014;121(12):2443-51.Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. Lancet. 2008;372(9647):1361-3.Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40-51.Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:Cd006127.Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med. 1994;154(19):2169-78.Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446-55.Rema M, Srivastava BK, Anitha B, Deepa R, Mohan V. Association of serum lipids with diabetic retinopathy in urban South Indians--the Chennai Urban Rural Epidemiology Study (CURES) Eye Study--2. Diabet Med. 2006;23(9):1029-36.Rooney D, Lye WK, Tan G, Lamoureux EL, Ikram MK, Cheng CY, et al. Body mass index and retinopathy in Asian populations with diabetes mellitus. Acta Diabetol. 2015;52(1):73-80.Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol. 2007;52(2):180-95.Lu J, Hou X, Zhang L, Jiang F, Hu C, Bao Y, et al. Association between body mass index and diabetic retinopathy in Chinese patients with type 2 diabetes. Acta Diabetol. 2015;52(4):701-8.Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006;12 Suppl 1:34-41.Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 2016;17(9).Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M. Up-regulation of vascular endothelial growth factor and down-regulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes. Int J Tissue React. 2002;24(4):137-42.Srinivasan V, Sulochana KN. Effect of adiponectin on expression of vascular endothelial growth factor and pigment epithelium-derived factor: An in vitro study. Indian Journal of Pharmacology. 2015;47(1):117-20.Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol. 2008;92(4):548-51.He R, Shen J, Liu F, Zeng H, Li L, Yu H, et al. Vitamin D deficiency increases the risk of retinopathy in Chinese patients with type 2 diabetes. Diabet Med. 2014;31(12):1657-64.Huang YC, Lin JM, Lin HJ, Chen CC, Chen SY, Tsai CH, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011;118(4):642-8.Fu YP, Hallman DM, Gonzalez VH, Klein BE, Klein R, Hayes MG, et al. Identification of Diabetic Retinopathy Genes through a Genome-Wide Association Study among Mexican-Americans from Starr County, Texas. J Ophthalmol. 2010;2010.Symposium on the Treatment of Diabetic R, Goldberg MF, Fine SL, Symposium on the Treatm EDR, editors. Symposium on the Treatment of Diabetic Retinopathy Airlie House, Warrenton, Virginia, September 29 to October 1, 19681969; Arlington, Va: U.S. Dep. of Health, Education, and Welfare, Public Health Service, Neurological and Sensory Disease Control Program, Diabetes and Arthritis Control Program.Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978;85(1):82-106.Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):823-33.Zhang X, Saaddine JB, Chou C-F, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of Diabetic Retinopathy in the United States, 2005–2008. JAMA : the journal of the American Medical Association. 2010;304(6):649-56.Fong DS, Ferris FL, 3rd, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127(2):137-41.Estacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis. 1998;31(6):947-53.Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-44.Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127(3):245-51.Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128(3):289-96.Stefanini FR, Badaro E, Falabella P, Koss M, Farah ME, Maia M. Anti-VEGF for the management of diabetic macular edema. J Immunol Res. 2014;2014:632307.Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, et al. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135(6):558-68.Shah AR, Gardner TW. Diabetic retinopathy: research to clinical practice. Clin Diabetes Endocrinol. 2017;3:9.Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2010;117(6):1064-77.e35.Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014(11):Cd011234.Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. Jama. 2015;314(20):2137-46.Kim JH, Kwon HS, Park YM, Lee JH, Kim MS, Yoon KH, et al. Prevalence and associated factors of diabetic retinopathy in rural Korea: the Chungju metabolic disease cohort study. J Korean Med Sci. 2011;26(8):1068-73.Rodriguez-Poncelas A, Miravet-Jimenez S, Casellas A, Barrot-De La Puente JF, Franch-Nadal J, Lopez-Simarro F, et al. Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). Br J Ophthalmol. 2015;99(12):1628-33.Alonso-Moran E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Marques Gonzalez ML, Toro Polanco N, et al. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. BMC Public Health. 2014;14:1059.Covarrubias T, Delgado I, Rojas D, Coria M. [Coverage of a screening program and prevalence of diabetic retinopathy in primary carec]. Rev Med Chil. 2017;145(5):564-71.Ruta LM, Magliano DJ, Lemesurier R, Taylor HR, Zimmet PZ, Shaw JE. Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. Diabet Med. 2013;30(4):387-98.Polack S, Yorston D, Lopez-Ramos A, Lepe-Orta S, Baia RM, Alves L, et al. Rapid assessment of avoidable blindness and diabetic retinopathy in Chiapas, Mexico. Ophthalmology. 2012;119(5):1033-40.Herman WH, Aubert RE, Engelgau MM, Thompson TJ, Ali MA, Sous ES, et al. Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet Med. 1998;15(12):1045-51.Kadiki OA, Roaed RB. Epidemiological and clinical patterns of diabetes mellitus in Benghazi, Libyan Arab Jamahiriya. East Mediterr Health J. 1999;5(1):6-13.Farnkvist LM, Lundman BM. Outcomes of diabetes care: a population-based study. Int J Qual Health Care. 2003;15(4):301-7.Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia. 2010;53(10):2147-54.Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. Prevalence and Risk Factors for Diabetic Retinopathy: The Singapore Malay Eye Study. Ophthalmology. 2008;115(11):1869-75.Thomas RL, Dunstan F, Luzio SD, Roy Chowdury S, Hale SL, North RV, et al.Furtado JM, Lansingh VC, Carter MJ, Milanese MF, Peña BN, Ghersi HA, et al. Causes of Blindness and Visual Impairment in Latin America. Survey of Ophthalmology. 2012;57(2):149-77.Cass H, Landers J, Benitez P. Causes of blindness among hospital outpatients in Ecuador. Clin Exp Ophthalmol. 2006;34(2):146-51.Cano MR. Prevalence of diabetic retinopathy and barriers to uptake of eye care services by diabetic patients at the Social Security Institute Central Hospital in Asunción, Paraguay. Community Eye Health. 2007;20(61):10-1.Alonso Porcel C, Martinez Iban M, Arboleya Alvarez L, Suarez Gil P, Sanchez Rodriguez LM. [Diabetic retinopathy screening programme in primary health care. Diagnostic concordance between family and eye care practitioners]. Semergen. 2016;42(6):357-62.instname:Universidad del Rosarioreponame:Repositorio Institucional EdocUREdema macularPrevalenciaRetinopatía diabéticaCegueraDiabetes mellitusEnfermedades616600retinal hemorrhagesdiabetes complicationsdiabetic retinopathymacular edemablindnessDiabetesEnfermedades de la retinaEnfermedades de los ojosPrevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017Retinopatía diabética : prevalencia en diabéticos tipo 2 en un hospital de referencia de Bogotá entre 2012 – 2017bachelorThesisTrabajo de gradohttp://purl.org/coar/resource_type/c_7a1fLICENSElicense.txtlicense.txttext/plain1475https://repository.urosario.edu.co/bitstreams/d322cbbc-0c8f-40ee-a7a4-624a839dc83e/downloadfab9d9ed61d64f6ac005dee3306ae77eMD52ORIGINALPREVALENCIA-DE-RETINOPATIA-DIABeTICA-EN-DIABeTICOS-TIPO-II-EN-UN-CENTRO-DE-REFERENCIA2012-2017.pdfPREVALENCIA-DE-RETINOPATIA-DIABeTICA-EN-DIABeTICOS-TIPO-II-EN-UN-CENTRO-DE-REFERENCIA2012-2017.pdfapplication/pdf901901https://repository.urosario.edu.co/bitstreams/999e97ea-21be-47c0-a22b-f40234c9b138/download7afffe0583fe869433be57a2109c5798MD53TEXTPREVALENCIA-DE-RETINOPATIA-DIABeTICA-EN-DIABeTICOS-TIPO-II-EN-UN-CENTRO-DE-REFERENCIA2012-2017.pdf.txtPREVALENCIA-DE-RETINOPATIA-DIABeTICA-EN-DIABeTICOS-TIPO-II-EN-UN-CENTRO-DE-REFERENCIA2012-2017.pdf.txtExtracted texttext/plain152114https://repository.urosario.edu.co/bitstreams/95079407-60ea-4137-b972-4787b9a5f96a/download606904216f1051bf3b6a9c923c6ac4e1MD54THUMBNAILPREVALENCIA-DE-RETINOPATIA-DIABeTICA-EN-DIABeTICOS-TIPO-II-EN-UN-CENTRO-DE-REFERENCIA2012-2017.pdf.jpgPREVALENCIA-DE-RETINOPATIA-DIABeTICA-EN-DIABeTICOS-TIPO-II-EN-UN-CENTRO-DE-REFERENCIA2012-2017.pdf.jpgGenerated Thumbnailimage/jpeg2834https://repository.urosario.edu.co/bitstreams/1f39aa37-c7b9-46ae-9039-7e438f9d6870/download1a47518809b81157395cb6c0617af19aMD5510336/18648oai:repository.urosario.edu.co:10336/186482020-11-01 01:01:02.023827https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.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

Prevalencia de retinopatía diabética en diabéticos tipo II en un centro de referencia 2012 – 2017

Publicaciones similares